Knowledge Tree
low-density lipoprotein cholesterol
Also known as: low-density lipoprotein cholesterol, low-density lipoprotein, LDL-C, LDL
Facts (11)
Sources
EBM Tools for Practice: Best Biomarkers for Inflammation lipid.org 8 facts
measurementIn the Canakinumab Anti-inflammatory Thrombosis Outcome Trial (CANTOS), lowering high-sensitivity C-reactive protein (hs-CRP) below 2 mg/L resulted in a 25% reduction in major adverse cardiovascular events (p<0.001) and a 31% reduction in cardiovascular mortality (p<0.0001), despite no change in low-density lipoprotein cholesterol (LDL-C).
claimThe Safety and Cardiovascular Event Efficacy of Bococizumab in High-Risk Patients (SPIRES) Trial showed that persistent elevation of high-sensitivity C-reactive protein (hs-CRP) at 14 weeks was associated with increased future cardiovascular events, even after low levels of low-density lipoprotein cholesterol (LDL-C) were achieved.
claimIn the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER), patients experienced the fewest cardiovascular events when achieving both a low-density lipoprotein cholesterol (LDL-C) <70 mg/dL and a high-sensitivity C-reactive protein (hs-CRP) <2 mg/L.
claimReductions in low-density lipoprotein (LDL) cause a decline in lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, which limits the predictive value of Lp-PLA2 in patients undergoing lipid-lowering therapy.
claimLipoprotein-Associated Phospholipase A2 (Lp-PLA2) is an enzyme produced by lymphocytes and activated macrophages that binds primarily to low-density lipoprotein (LDL) in the serum.
claimThe Reversing Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial reported that regression of vascular disease occurred only in the group of patients who achieved low levels of both low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP).
claimThe Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) and the Pravastatin or Atorvastatin Evaluation and Infection Therapy Trial (PROVE-IT) showed that patients who met both targets of low-density lipoprotein cholesterol (LDL-C) <70 mg/dL and high-sensitivity C-reactive protein (hs-CRP) <2 mg/L had the best clinical outcomes.
claimIn the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), baseline levels of C-reactive protein (CRP) and low-density lipoprotein cholesterol (LDL-C) were comparable in identifying patient subsets at risk of future cardiovascular events.
Research reveals devastating impact of Western diet on human health news-medical.net Jun 18, 2023 1 fact
claimHigh-fat diets, such as the Western diet, result in unfavorable lipid profiles characterized by increased low-density-lipoprotein (LDL) levels and decreased high-density lipoprotein (HDL) levels, which leads to endothelial dysfunction.
Origins and evolution of the Western diet: health implications for the ... academia.edu 1 fact
referenceRidker PM, Rifai N, Rose L, Buring JE, and Cook NR compared the predictive value of C-reactive protein and low-density lipoprotein cholesterol levels for first cardiovascular events in a 2002 study published in the New England Journal of Medicine.
Pharmacological Uses of New Bioactive Compounds from Medicinal ... academia.edu 1 fact
claimTriterpenoids derived from the plant Protorhus longifolia exhibit hypocholesterolemic potential by regulating cholesterol biosynthesis and stimulating low-density lipoprotein uptake in HepG2 cells, as reported by Ndlovu et al. in 2023.